RNF43 and mismatch repair cancer syndrome 1: Previous research has indicated that RNF43 mutations are closely correlated with MSI, TMB, and mismatch repair deficiency (dMMR) phenotype in colon cancer patients, indicative of the promising potential of the combination of immune checkpoint inhibitors with Wnt/β-catenin signaling pathways inhibitors as a reasonable therapeutic strategy in cancer treatment [54].